Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
PLoS One ; 12(8): e0182799, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28813492

RESUMO

BACKGROUND: The correlation of Clostridium difficile infection (CDI) with in-hospital morbidity is important in hospital settings where broad-spectrum antimicrobial agents are routinely used, such as in Greece. The C. DEFINE study aimed to assess point-prevalence of CDI in Greece during two study periods in 2013. METHODS: There were two study periods consisting of a single day in March and another in October 2013. Stool samples from all patients hospitalized outside the ICU aged ≥18 years old with diarrhea on each day in 21 and 25 hospitals, respectively, were tested for CDI. Samples were tested for the presence of glutamate dehydrogenase antigen (GDH) and toxins A/B of C. difficile; samples positive for GDH and negative for toxins were further tested by culture and PCR for the presence of toxin genes. An analysis was performed to identify potential risk factors for CDI among patients with diarrhea. RESULTS: 5,536 and 6,523 patients were screened during the first and second study periods, respectively. The respective point-prevalence of CDI in all patients was 5.6 and 3.9 per 10,000 patient bed-days whereas the proportion of CDI among patients with diarrhea was 17% and 14.3%. Logistic regression analysis revealed that solid tumor malignancy [odds ratio (OR) 2.69, 95% confidence interval (CI): 1.18-6.15, p = 0.019] and antimicrobial administration (OR 3.61, 95% CI: 1.03-12.76, p = 0.045) were independent risk factors for CDI development. Charlson's Comorbidity Index (CCI) >6 was also found as a risk factor of marginal statistical significance (OR 2.24, 95% CI: 0.98-5.10). Median time to CDI from hospital admission was shorter with the presence of solid tumor malignancy (3 vs 5 days; p = 0.002) and of CCI >6 (4 vs 6 days, p = 0.009). CONCLUSIONS: The point-prevalence of CDI in Greek hospitals was consistent among cases of diarrhea over a 6-month period. Major risk factors were antimicrobial use, solid tumor malignancy and a CCI score >6.


Assuntos
Clostridioides difficile , Infecções por Clostridium/epidemiologia , Infecções por Clostridium/microbiologia , Infecção Hospitalar , Hospitais , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Biomarcadores , Infecções por Clostridium/diagnóstico , Infecções por Clostridium/tratamento farmacológico , Comorbidade , Diarreia/epidemiologia , Diarreia/microbiologia , Feminino , Grécia/epidemiologia , Instalações de Saúde , Hospitalização , Humanos , Masculino , Pessoa de Meia-Idade , Razão de Chances , Vigilância da População , Prevalência , Modelos de Riscos Proporcionais , Fatores de Risco , Sensibilidade e Especificidade
2.
Eur J Pediatr ; 174(1): 65-74, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24985124

RESUMO

UNLABELLED: The investigation and successful management of a monoclonal Acinetobacter baumannii outbreak in a neonatal intensive care unit are described. Upon the first clustered carbapenem-resistant A. baumannii (CRAB) infections, a bundle of actions were taken, including enhanced infection control, active surveillance (weekly stool samples), case-control study, staff education, daily audits and discontinuation of new admissions. Between September and December 2011, eight neonates developed 10 CRAB infections (five blood, four respiratory and one eye). A total of 216 active surveillance cultures were obtained from 96 neonates (43 % had ≥2 samples). During weeks 12, 16 and 17, active surveillance detected 3, 1 and 2 new CRAB acquisitions, respectively. Prevalence of infections/colonizations decreased, and no event occurred after 20th week. A colonized neonate developed CRAB sepsis and died. All CRAB isolates harboured bla OXA-58 and the intrinsic chromosomal bla OXA-51 carbapenemase genes. CONCLUSION: Active surveillance and enhanced infection control measures effectively contained spread of CRAB clone in the neonatal intensive care unit.


Assuntos
Infecções por Acinetobacter/tratamento farmacológico , Infecções por Acinetobacter/epidemiologia , Acinetobacter baumannii/isolamento & purificação , Surtos de Doenças , Resistência beta-Lactâmica , Infecções por Acinetobacter/microbiologia , Acinetobacter baumannii/efeitos dos fármacos , Acinetobacter baumannii/genética , Antibacterianos/uso terapêutico , Carbapenêmicos/efeitos adversos , Colistina/uso terapêutico , Fezes/microbiologia , Humanos , Recém-Nascido , Unidades de Terapia Intensiva Neonatal , Meropeném , Estudos Prospectivos , Tienamicinas/uso terapêutico , beta-Lactamases/genética
3.
New Microbiol ; 35(4): 503-6, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23109020

RESUMO

Ralstonia mannitolilytica constitutes a rare isolate in clinical specimens and to date very few infections with this Gramnegative bacillus have been reported. The first case of peritonitis in a pediatric patient due to R. mannitolilytica in the setting of peritoneal dialysis is described. It is very important to view this organism as a pathogen rather than contaminant when isolated in children with peritonitis.


Assuntos
Diálise Peritoneal/efeitos adversos , Peritonite/microbiologia , Ralstonia/isolamento & purificação , Antibacterianos/farmacologia , Criança , Feminino , Humanos , Peritonite/etiologia , Ralstonia/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA